keyword
MENU ▼
Read by QxMD icon Read
search

High dose influenza vaccine

keyword
https://www.readbyqxmd.com/read/29909156/high-dose-influenza-vaccine-to-reduce-clinical-outcomes-in-high-risk-cardiovascular-patients-rationale-and-design-of-the-invested-trial
#1
Orly Vardeny, Jacob A Udell, Jacob Joseph, Michael E Farkouh, Adrian F Hernandez, Alison J McGeer, H Keipp Talbot, Deepak L Bhatt, Christopher P Cannon, Shaun G Goodman, Inder Anand, David L DeMets, Jon Temte, Janet Wittes, Kristin Nichol, Clyde W Yancy, J Michael Gaziano, Lawton S Cooper, KyungMann Kim, Scott D Solomon
BACKGROUND: Influenza leads to significant cardiopulmonary morbidity and mortality-particularly in patients with cardiovascular disease-that may be prevented with a standard influenza vaccine. However, patients with cardiovascular conditions have a reduced immune response to influenza vaccine, potentially resulting in reduced effectiveness for preventing clinical events. High-dose vaccine augments immune response in cardiac patients, suggesting that a high-dose influenza vaccination strategy may further reduce morbidity and mortality...
May 23, 2018: American Heart Journal
https://www.readbyqxmd.com/read/29899269/a-simple-and-robust-approach-for-evaluation-of-antivirals-using-a-recombinant-influenza-virus-expressing-gaussia-luciferase
#2
Ping Li, Qinghua Cui, Lin Wang, Xiujuan Zhao, Yingying Zhang, Balaji Manicassamy, Yong Yang, Lijun Rong, Ruikun Du
Influenza A virus (IAV) causes seasonal epidemics and occasional but devastating pandemics, which are major public health concerns. Because the effectiveness of seasonal vaccines is highly variable and the currently available drugs are limited in their efficacy because of the emergence of drug resistance, there is an urgent need to develop novel antivirals. In this study, we characterized a recombinant IAV-carrying Gaussia luciferase (Gluc) gene and determined its potential as a tool for evaluating therapeutics...
June 13, 2018: Viruses
https://www.readbyqxmd.com/read/29885802/cross-immunity-of-a-h9n2-live-attenuated-influenza-vaccine-against-h5n2-highly-pathogenic-avian-influenza-virus-in-chickens
#3
Mingyang Wang, Yandi Wei, Juan Pu, Guoxia Bing, Yipeng Sun, Honglei Sun, Fanhua Wei, Jinhua Liu
The most commonly utilized inactivated influenza vaccines (IIVs) are usually deficient in cross immunity against divergent viruses. On the other hand, live attenuated influenza vaccines (LAIVs) are proved to be more effective in cross-protective immunity. We previously developed a H9N2 LAIV and verified its effective protection against a broad spectrum of H9N2 strains. In the present study, we evaluated its cross-immunity against H5N2 virus, a representative subtype of currently predominant H5 highly pathogenic avian influenza viruses...
July 2018: Veterinary Microbiology
https://www.readbyqxmd.com/read/29859802/influenza-vaccination-for-hiv-positive-people-systematic-review-and-network-meta-analysis
#4
Wei Zhang, Huiying Sun, Mohammad Atiquzzaman, Julie Sou, Aslam H Anis, Curtis Cooper
BACKGROUND: People with Human Immunodeficiency Virus (HIV) are highly susceptible to influenza-related morbidity and mortality. In order to assess comparative efficacy of influenza vaccine strategies among HIV-positive people, we performed a systematic review and Bayesian network meta-analysis (NMA). METHODS: In this systematic review, we searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL between 1946 and July 2015 for randomized controlled trials (RCTs) on influenza vaccines for HIV-positive adults reporting seroconversion or seroprotection outcomes...
May 30, 2018: Vaccine
https://www.readbyqxmd.com/read/29783025/immunogenicity-and-reactogenicity-of-high-versus-standard-dose-trivalent-inactivated-influenza-vaccine-in-healthcare-workers-a-pilot-randomized-controlled-trial
#5
C Volling, B L Coleman, K Katz, A E Simor, M Muller, J Powis, J McElhaney, A McGeer
OBJECTIVES: To compare immunogenicity, reactogenicity and acceptability of high- and standard-dose trivalent inactivated influenza vaccine (HDTIV, SDTIV) in 18-64 year olds. METHODS: We randomized 18-64-year-olds to HDTIV or SDTIV in two consecutive years. We collected serum on Days 0 and 21, measured hemagglutination inhibition (HAI) titers, and compared seroconversion, Day 21 titers, seroprotection, reactogenicity, acceptability. RESULTS: Immunogenicity was evaluable in 42 of 47 2014 participants, all 33 both year participants, and 87 of 90 2015-only participants...
May 18, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29779922/safety-tolerability-acceptability-and-immunogenicity-of-an-influenza-vaccine-delivered-to-human-skin-by-a-novel-high-density-microprojection-array-patch-nanopatch%C3%A2
#6
Germain J P Fernando, Julian Hickling, Cesar M Jayashi Flores, Paul Griffin, Christopher D Anderson, S Rachel Skinner, Cristyn Davies, Katey Witham, Melinda Pryor, Jesse Bodle, Steve Rockman, Ian H Frazer, Angus H Forster
BACKGROUND: Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk of needle-stick injury, and the need to reconstitute lyophilised vaccines, are also drawbacks. The Nanopatch (NP) is a microarray skin patch comprised of a high-density array of microprojections dry-coated with vaccine that is being developed to address these shortcomings. Here we report a randomised, partly-blinded, placebo-controlled trial that represents the first use in humans of the NP to deliver a vaccine...
May 17, 2018: Vaccine
https://www.readbyqxmd.com/read/29771697/influenza-vaccine-strategies-for-solid-organ-transplant-recipients
#7
Cédric Hirzel, Deepali Kumar
PURPOSE OF REVIEW: The aim of this study was to highlight recent evidence on important aspects of influenza vaccination in solid organ transplant recipients. RECENT FINDINGS: Influenza vaccine is the most evaluated vaccine in transplant recipients. The immunogenicity of the vaccine is suboptimal after transplantation. Newer formulations such as inactivated unadjuvanted high-dose influenza vaccine and the administration of a booster dose within the same season have shown to increase response rates...
May 15, 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29767756/influenza-vaccination-coverage-among-us-children-from-2004-2005-to-2015-2016
#8
Changwei Tian, Hua Wang, Wenming Wang, Xiaoming Luo
Background: Quantify the influenza vaccine coverage is essential to identify emerging concerns and to immunization programs for targeting interventions. Methods: Data from National Health Interview Survey were used to estimate receipt of at least one dose of influenza vaccination among children 6 months to 17 years of age. Results: Influenza vaccination coverage increased from 16.70% during 2004/2005 to 49.43% during 2015/2016 (3.18% per year, P < 0...
May 15, 2018: Journal of Public Health
https://www.readbyqxmd.com/read/29762363/immunogenicity-and-safety-of-primary-and-booster-vaccinations-of-a-fully-liquid-dtap-ipv-hb-prp-t-hexavalent-vaccine-in-healthy-infants-and-toddlers-in-germany-and-the-czech-republic
#9
Roman Prymula, Dorothee Kieninger, Emmanuel Feroldi, Emilia Jordanov, Siham B'Chir, Xavier DaCosta
BACKGROUND: To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11 to 15 months of age. METHODS: Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (Group 1; N=266) or a reconstituted DTaPHB-IPV//PRP-T comparator (Group 2; N=263) and a booster of the same vaccine...
May 14, 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29752131/effectiveness-of-the-dtpa-hbv-ipv-hib-vaccine-against-invasive-haemophilus-influenzae-type-b-disease-in-the-netherlands-2003-16-a-case-control-study
#10
Susana Monge, Susan Jm Hahné, Hester E de Melker, Elisabeth Am Sanders, Arie van der Ende, Mirjam J Knol
BACKGROUND: In 2016, an increase in invasive Haemophilus influenzae serotype b (Hib) disease was reported in the Netherlands in children younger than 5 years, which coincided with the introduction of the hexavalent diphtheria, tetanus, and acellular pertussis-hepatitis B virus-inactivated polio virus/Hib vaccine (DTPa-HBV-IPV/Hib) from 2011 onwards. We aimed to estimate the effectiveness of the hexavalent vaccine to assess whether this increase could be explained by decreasing effectiveness...
May 8, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29748031/multimorbidity-is-associated-with-uptake-of-influenza-vaccination
#11
Samantha M Harrison, Melissa Y Wei, Lois E Lamerato, Joshua G Petrie, Emily Toth Martin
OBJECTIVE: Patients with chronic conditions have higher rates of severe influenza-related illness and mortality. However, influenza vaccination coverage in high-risk populations continues to be suboptimal. We describe the association between cumulative disease morbidity, measured by a previously validated multimorbidity index, and influenza vaccination among community-dwelling adults. METHODS: We obtained interview and medical record data for participants  ≥18 years who sought outpatient care for influenza-like illness between 2011 and 2016 as part of an outpatient-based study of influenza vaccine effectiveness...
May 7, 2018: Vaccine
https://www.readbyqxmd.com/read/29741717/influenza-associated-acute-necrotizing-encephalopathy-in-siblings
#12
Ashley Howard, Timothy M Uyeki, Jaime Fergie
Encephalopathy is an important complication associated with influenza, most frequently observed in young children, with a wide range of severity. The most severe category of influenza-associated encephalopathy (IAE) is acute necrotizing encephalopathy (ANE), characterized by high frequency of neurologic sequelae and fatal outcomes. We report two young siblings who developed fever and seizures with altered mental status. Influenza A(H1N1)pdm09 virus infection was identified in upper respiratory tract specimens from both patients, and neuroimaging revealed bilateral inflammatory lesions, consistent with acute necrotizing encephalopathy...
May 4, 2018: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/29715054/efficacy-and-effectiveness-of-high-dose-versus-standard-dose-influenza-vaccination-for-older-adults-a-systematic-review-and-meta-analysis
#13
Jason K H Lee, Gary K L Lam, Thomas Shin, Jiyeon Kim, Anish Krishnan, David P Greenberg, Ayman Chit
BACKGROUND: Influenza is responsible for a significant disease burden annually, especially in older adults. This study reviews the relative vaccine efficacy or effectiveness (rVE) of high-dose inactivated trivalent influenza vaccine (HD-IIV3) compared to standard-dose influenza vaccines (IIV3) in adults ≥65 against influenza-associated outcomes to inform evidence-based decision-making to shift clinical practice and standard of care in this population. METHODS: A systematic review was conducted for studies assessing the rVE of HD-IIV3 against probable/laboratory-confirmed influenza-like illness (ILI), hospital admissions, and death in adults ≥65...
May 1, 2018: Expert Review of Vaccines
https://www.readbyqxmd.com/read/29688839/influenza-vaccination-protects-against-pandemic-h1n1-infection-in-sickle-cell-disease-mice
#14
Sean Roberts, Dennis W Metzger, Steven M Szczepanek
Influenza infection is associated with enhanced pathology in individuals with sickle cell disease (SCD). Despite being a high priority group for annual influenza vaccination, little is known about long-term responses to influenza vaccination in this patient population. To model flu vaccination, we inoculated SCD and wild type (WT) littermate mice with the seasonal flu vaccine [containing pandemic H1N1 (pH1N1) antigen], bled the mice before and after vaccination, and intranasally challenged them with a high dose (400 PFU) of pH1N1 12 weeks later...
April 24, 2018: Viral Immunology
https://www.readbyqxmd.com/read/29670610/neonatal-immunization-rationale-current-state-and-future-prospects
#15
REVIEW
Elizabeth Whittaker, David Goldblatt, Peter McIntyre, Ofer Levy
Infections take their greatest toll in early life necessitating robust approaches to protect the very young. Here, we review the rationale, current state, and future research directions for one such approach: neonatal immunization. Challenges to neonatal immunization include natural concern about safety as well as a distinct neonatal immune system that is generally polarized against Th1 responses to many stimuli such that some vaccines that are effective in adults are not in newborns. Nevertheless, neonatal immunization could result in high-population penetration as birth is a reliable point of healthcare contact, and offers an opportunity for early protection of the young, including preterm newborns who are deficient in maternal antibodies...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29660994/providing-additional-muscle-for-older-adults-through-optimal-influenza-vaccine-selection
#16
John A Dougherty, Elias B Chahine
Immunization is the best strategy to protect individuals from influenza; however, older adults tend to respond less favorably to vaccines because of immunosenescence. The Centers for Disease Control and Prevention states that any licensed, recommended, and age-appropriate influenza vaccine may be used in older adults despite reasonable evidence suggesting that the high-dose and, to a lesser extent, the adjuvanted and recombinant influenza vaccines provide better protection than the standard-dose vaccines in this vulnerable population...
April 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29624615/efficacy-and-synergy-of-live-attenuated-and-inactivated-influenza-vaccines-in-young-chickens
#17
Hyesun Jang, Mohamed Elaish, Mahesh Kc, Michael C Abundo, Amir Ghorbani, John M Ngunjiri, Chang-Won Lee
Outbreaks of novel highly pathogenic avian influenza viruses have been reported in poultry species in the United States since 2014. These outbreaks have proven the limitations of biosecurity control programs, and new tools are needed to reinforce the current avian influenza control arsenal. Some enzootic countries have implemented inactivated influenza vaccine (IIV) in their control programs, but there are serious concerns that a long-term use of IIV without eradication may result in the selection of novel antigenically divergent strains...
2018: PloS One
https://www.readbyqxmd.com/read/29620467/the-effect-of-infectious-bursal-disease-virus-induced-immunosuppression-on-vaccination-against-highly-pathogenic-avian-influenza-virus
#18
Erica Spackman, Christopher B Stephens, Mary J Pantin-Jackwood
Poor efficacy of avian influenza virus (AIV) vaccines in chickens has been documented in the field in spite of good results in experimental settings. Although the causes are multifactorial and complex, one contributing factor may be prior infection with immunosuppressive viruses. In an effort to evaluate the role of immunosuppressive agents on AIV pathogenesis and vaccine efficacy, the effect of prior infection with infectious bursal disease virus (IBDV), a ubiquitous immunosuppressive virus of chickens, was evaluated...
March 2018: Avian Diseases
https://www.readbyqxmd.com/read/29617814/a-respiratory-syncytial-virus-vaccine-based-on-the-small-hydrophobic-protein-ectodomain-presented-with-a-novel-lipid-based-formulation-is-highly-immunogenic-and-safe-in-adults-a-first-in-humans-study
#19
Joanne M Langley, Lisa D MacDonald, Genevieve M Weir, Donna MacKinnon-Cameron, Lingyun Ye, Shelly McNeil, Bert Schepens, Xavier Saelens, Marianne M Stanford, Scott A Halperin
Background: Respiratory Syncytial Virus infection can cause lower respiratory tract infection in older adults comparable to influenza, but no vaccines are available. Methods: This was a randomized, observer blinded first-in-humans study of a novel synthetic RSV antigen SHe, formulated with either the lipid and oil-based vaccine platform, DepoVaxTM, termed DPX-RSV(A), or with alum, termed (RSV(A) SHe, in healthy 50-64-year-old adults. Two dose levels (10 or 25 µg) of the SHe antigen with each formulation were compared to placebo...
March 30, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29615248/a-two-dose-immunization-with-an-inactivated-reassortant-h5n2-virus-protects-chickens-against-lethal-challenge-with-homologous-2-3-2-1-clade-and-heterologous-2-2-clade-highly-pathogenic-avian-influenza-h5n1-viruses
#20
Sushant Bhat, Richa Sood, Shweta Shukla, Rekha Khandia, Atul Kumar Pateriya, Naveen Kumar, Vikas Kumar Singh, Semmannan Kalaiyarasu, Manoj Kumar, Sandeep Bhatia
The present study was aimed at generating a reassortant vaccine candidate virus with clade 2.3.2.1 Hemagglutinin (HA) and its evaluation in a challenge study for protection against homologous (2.3.2.1 clade) and heterologous (2.2 clade) highly pathogenic avian influenza (HPAI) H5N1 viruses. Plasmid-based reverse genetics technique was used to rescue a 5 + 3 reassortant H5N2 strain containing the modified HA of H5N1 (clade 2.3.2.1), the Neuraminidase (NA) of H9N2, the Matrix (M) of H5N1 and the internal genes of A/WSN/33 H1N1...
April 2018: Veterinary Microbiology
keyword
keyword
116341
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"